Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

Recruiting now · Not applicable

Conditions studied: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma

In brief

This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organ. Giving SABR before surgery may make the tumor smaller. Adding dietary restrictions in combination with radiation therapy may help increase local control and decrease the spread of the cancer to other places in the body. The purpose of this trial is to identify if there is a decrease in tumor tissue in patients undergoing caloric restriction during pre-operative SABR, compared to patients undergoing pre-operative SABR alone.

Key facts

Study ID

NCT04959474

Run by

Thomas Jefferson University

People needed

80

Starts

2021-08-23

Expected to finish

2028-11-01

Last updated by the study team

2026-01-23

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Patients with pathologically proven DCIS or invasive breast cancer histologies
• Willing and able to provide informed consent
• Willing and able to comply with study treatments including dietary intervention
• Body mass index (BMI) >= 21 at time of enrollment
• Age >= 40 years at time of consent
• Patients with triple negative breast cancer (TNBC) must be >= 50 years of age at time of consent
• Karnofsky performance status (KPS) score 70 - 100
• Tumor size =< 3.0 cm
• Gross disease within the breast must be unifocal
• Gross disease may be multifocal as long as the total extent of tumor, gross and microscopic, occupies a volume with greatest dimension =< 3 cm
• Patients with invasive disease are required to have clinical axillary staging including axillary ultrasound (US) that proves patient is clinically node negative or can be done by physical examination if the patient is over 70
• Patient is not being considered for preoperative chemotherapy
• Must be English or Spanish speaking

You may not qualify if…

• Patient is clinically node positive: clinically suspicious axillary lymph node(s) by axillary US or exam unless biopsied and found to be negative
• Patient has stage IV metastatic disease
• Patients with oligo-metastatic disease who are being treated with curative intent per the treating physician will not be excluded if all other eligibility criteria are met
• Breast tumor size is > 3.0 cm
• Positive non-axillary sentinel nodes or evidence of suspicious supraclavicular, infraclavicular, or internal mammary nodes by imaging or physical exam, unless biopsied and found to be negative for tumor
• Evidence by physical examination or mammography of other suspicious masses, densities, or microcalcifications in either breast, unless biopsied and found to be benign
• Paget's disease of the nipple
• Previous breast radiation on ipsilateral side
• Any prior treatment with radiation therapy or chemotherapy for the current breast cancer diagnosis prior to registration
• Patients with significant psychiatric illness that would preclude them from adhering to the protocol in the judgement of the treating clinician
• BMI < 21 at the time of study enrollment

Where it is running

• Thomas Jefferson University Hospital — Philadelphia, Pennsylvania, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.